

POLICY TITLE	THERMAL CAPSULORRHAPHY AS A TREATMENT OF JOINT INSTABILITY
POLICY NUMBER	MP 1.086

CLINICAL BENEFIT	□ MINIMIZE SAFETY RISK OR CONCERN.
	☑ MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS.
	ASSURE APPROPRIATE LEVEL OF CARE.
	□ ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS.
	□ ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET.
	□ ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective Date:	4/1/2025

<u>POLICY</u>
RATIONALE
DISCLAIMER
POLICY HISTORY

PRODUCT VARIATIONS DEFINITIONS CODING INFORMATION DESCRIPTION/BACKGROUND BENEFIT VARIATIONS REFERENCES

I. POLICY

Thermal capsulorrhaphy is considered **investigational** as a treatment of joint instability. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

II. PRODUCT VARIATIONS

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations as discussed in Section VI. Please see additional information below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at: <u>https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies</u>.

III. DESCRIPTION/BACKGROUND

Thermal capsulorrhaphy uses thermal energy to restructure collagen in the capsule or ligaments to reduce the capsule size. This procedure has primarily been evaluated for shoulder joint instability but may also be proposed to treat capsular laxity in other joints.

Shoulder instability is a common occurrence, reported in between 2% and 8% of the population. The condition may arise from a single traumatic event (i.e., subluxation or dislocation), repeated microtrauma or constitutional ligamentous laxity, resulting in deformation and/or damage in the glenohumeral capsule and ligaments. Shoulder instability may be categorized according to the movement of the humeral head: anterior, posterior, inferior, or multidirectional instability.

Surgery consists of inspection of the shoulder joint with repair, reattachment, or tightening of the labrum, ligaments, or capsule, performed either with sutures or sutures attached to absorbable tacks or anchors. While arthroscopic approaches have been investigated over the past decade,

Тор

Top



POLICY TITLE	THERMAL CAPSULORRHAPHY AS A TREATMENT OF JOINT INSTABILITY
POLICY NUMBER	MP 1.086

their success has been controversial due to a higher rate of recurrent instability compared with open technique. This is thought to be related in part to the lack of restoration of capsular tension. Reports of arthroscopic techniques have described various suturing techniques for tightening the capsule, which require mastery of technically difficult arthroscopic intra-articular knot tying.

Thermal capsulorrhaphy has been proposed as a simpler arthroscopic technique for tightening the capsule and ligaments. This technique utilizes non-ablative levels of radiofrequency thermal energy to alter the collagen in the glenohumeral ligaments and/or capsule, resulting in their shrinkage and a decrease in capsular volume, both thought to restore capsular tension. Thermal capsulorrhaphy may be used in conjunction with arthroscopic repair of torn ligaments or other structures (i.e., repair of Bankart or superior labrum anterior and posterior lesion). Thermal capsulorrhaphy has also been considered in patients with congenital ligamentous laxity, such as Ehlers-Danlos or Marfan's syndrome.

Thermal capsulorrhaphy has also been investigated as treatment for instability of the hip, ankle, hand, and wrist.

While thermal capsulorrhaphy was initially investigated using laser energy, the use of radiofrequency probes is now more commonly used. Devices include Oratec ORA-50 Monopolar RF Generator (Oratec Interventions, Menlo Park, CA) and Arthrocare (Arthrocare Corporation, Sunnyvale, CA).

IV. RATIONALE

Summary of Evidence

The literature does not support use of thermal capsulorrhaphy. The few available comparative studies do not support that this procedure is an efficacious treatment for shoulder instability. The case series report a high rate of unsatisfactory results and complications, raising the potential for a net harm. Reported complications have included capsular necrosis, loss of capsular and glenohumeral ligament integrity, chondrolysis, nerve damage, and failure leading to recurrent instability. The evidence does not demonstrate positive health outcomes.

V. **DEFINITIONS**

CAPSULORRHAPHY refers to suture of a joint capsule or a tear in a capsule.

GLENOHUMERAL pertains to the humerus and the glenoid cavity.

MICROINSTABILITY refers to instability due to particle/Kinetic-theoretical effects, typically occurring on small scales, as opposed to those derivable from fluid models valid on larger scales.

MICROTRAUMA refers to a very small injury.

RADIOFREQUENCY refers to radiant energy of a certain frequency range.

SUBLUXATION refers to a partial or incomplete dislocation.

Top

Тор



POLICY TITLE	THERMAL CAPSULORRHAPHY AS A TREATMENT OF JOINT INSTABILITY
POLICY NUMBER	MP 1.086

VI. BENEFIT VARIATIONS

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations are based on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. Members and providers should consult the member's health benefit plan for information or contact Capital Blue Cross for benefit information.

VII. DISCLAIMER

Capital Blue Cross' medical policies are developed to assist in administering a member's benefits. These medical policies do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital Blue Cross' Provider Services or Member Services. Capital Blue Cross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Thermal capsulorrhaphy is considered **investigational** as a treatment of joint instability, including, but not limited to the shoulder, knee, and elbow; therefore, not covered:

Procedure Codes								
29999	S2300							

IX. REFERENCES

- 1. Abrams JS. Thermal capsulorrhaphy for instability of the shoulder: concerns and applications of the heat probe. Instr Course Lect. 2001;50:29-36. PMID 11372327
- 2. Gryler EC, Greis PE, Burks RT, et al. Axillary nerve temperatures during radiofrequency capsulorrhaphy of the shoulder. Arthroscopy. Jul 2001;17(6):567-572. PMID 11447541
- Mohtadi NG, Hollinshead RM, Ceponis PJ, et al. A multi-centre randomized controlled trial comparing electrothermal arthroscopic capsulorrhaphy versus open inferior capsular shift for patients with shoulder instability: protocol implementation and interim performance: lessons learned from conducting a multi-centre RCT [ISRCTN68224911; NCT00251160]. Trials. 2006; 7:4. PMID 16542033

Top

Тор

Тор

Top



POLICY TITLE	THERMAL CAPSULORRHAPHY AS A TREATMENT OF JOINT INSTABILITY
POLICY NUMBER	MP 1.086

- 4. Levitz CL, Dugas J, Andrews JR. The use of arthroscopic thermal capsulorrhaphy to treat internal impingement in baseball players. Arthroscopy. Jul 2001;17(6):573-577. PMID 11447542
- 5. Savoie FH, 3rd, Field LD. Thermal versus suture treatment of symptomatic capsular laxity. Clin Sports Med. Jan 2000;19(1):63-75, vi. PMID 10652665
- Chen S, Haen PS, Walton J, et al. The effects of thermal capsular shrinkage on the outcomes of arthroscopic stabilization for primary anterior shoulder instability. Am J Sports Med. May 2005;33(5):705-711. PMID 15722277
- 7. Levy O, Wilson M, Williams H, et al. Thermal capsular shrinkage for shoulder instability. Mid-term longitudinal outcome study. J Bone Joint Surg Br. Jul 2001;83(5):640-645. PMID 11476296
- 8. D'Alessandro DF, Bradley JP, Fleischli JE, et al. Prospective evaluation of thermal capsulorrhaphy for shoulder instability: indications and results, two- to five-year follow-up. Am J Sports Med. Jan-Feb 2004;32(1):21-33. PMID 14754720
- 9. Levine WN, Bigliani LU, Ahmad CS. Thermal capsulorrhaphy. Orthopedics. Aug 2004;27(8):823-826. PMID 15369001
- Hawkins RJ, Krishnan SG, Karas SG, et al. Electrothermal arthroscopic shoulder capsulorrhaphy: a minimum 2-year follow-up. Am J Sports Med. Sep 2007;35(9):1484-1488. PMID 17456642
- Jansen N, Van Riet RP, Meermans G, et al. Thermal capsulorrhaphy in internal shoulder impingement: a 7-year follow-up study. Acta Orthop Belg. Jun 2012;78(3):304-308. PMID 22822568
- 12. Mason WT, Hargreaves DG. Arthroscopic thermal capsulorrhaphy for palmar midcarpal instability. J Hand Surg Eur Vol. Aug 2007;32(4):411-416. PMID 17950196
- 13. Zheng N, Davis BR, Andrews JR. The effects of thermal capsulorrhaphy of medial parapatellar capsule on patellar lateral displacement. J Orthop Surg Res. 2008;3:45. PMID 18826583
- 14. Good CR, Shindle MK, Kelly BT, et al. Glenohumeral chondrolysis after shoulder arthroscopy with thermal capsulorrhaphy. Arthroscopy. Jul 2007;23(7):797 e791-795. PMID 17637423
- 15. Lubowitz JH, Poehling GG. Glenohumeral thermal capsulorrhaphy is not recommended--shoulder chondrolysis requires additional research. Arthroscopy. Jul 2007;23(7):687. PMID 17637401
- 16. Johnson SM, Robinson CM. Shoulder instability in patients with joint hyperlaxity. J Bone Joint Surg Am. Jun 2010;92(6):1545-1557. PMID 20516333
- 17. Virk SS, Kocher MS. Adoption of new technology in sports medicine: case studies of the Gore-Tex prosthetic ligament and of thermal capsulorrhaphy. Arthroscopy. Jan 2011;27(1):113-121. PMID 20974526
- Gaunt BW, Shaffer MA, Sauers EL, et al. The American Society of Shoulder and Elbow Therapists' consensus rehabilitation guideline for arthroscopic anterior capsulolabral repair of the shoulder. J Orthop Sports Phys Ther. 2010;40(3):155-168. doi:10.2519/jospt.2010.3186 PMID: 20195022
- Engelbert RH, Juul-Kristensen B, Pacey V, et al. The evidence-based rationale for physical therapy treatment of children, adolescents, and adults diagnosed with joint hypermobility syndrome/hypermobile Ehlers Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):158-167. doi:10.1002/ajmg.c.31545 PMID: 28306230



POLICY TITLE	THERMAL CAPSULORRHAPHY AS A TREATMENT OF JOINT INSTABILITY
POLICY NUMBER	MP 1.086

- 20. UpToDate Online Journal [serial online]. Berkoff, D: Multidirectional instability of the shoulder. UpToDate; updated December 07, 2023. Literature review current through December 2024.
- 21. McRae S, Leiter J, Subramanian K, et al. Randomized controlled trial of arthroscopic electrothermal capsulorrhaphy with Bankart repair and isolated arthroscopic Bankart repair. Knee Surg Sports Traumatol Arthrosc. 2016; 24(2):414-421 PMID: 25711628
- 22. Rolfes K. Arthroscopic treatment of shoulder instability: a systematic review of capsular plication versus thermal capsulorrhaphy. J Athl Train. 2015;50(1):105-109. doi:10.4085/1062-6050-49.3.63 PMID: 25329347
- 23. Burn MB, Sarkissian EJ, Yao J. Long-Term Outcomes for Arthroscopic Thermal Treatment for Scapholunate Ligament Injuries. J Wrist Surg. 2020;9(1):22-28. doi:10.1055/s-0039-1693973. PMID: 32025350
- 24. Blue Cross Blue Shield Association Medical Policy Reference Manual. 7.01.82, Thermal Capsulorrhaphy as a Treatment of Joint Instability. June 2015 (Archived).

X. POLICY HISTORY

<u>Top</u>

MP 1.086	07/13/2020 Consensus Review. Policy statement unchanged. Product and
	Benefit variations as well as Disclaimer updated. FEP policy reference removed
	as no longer effective. References updated.
	05/21/2021 Consensus Review. Product Variations updated. No change to
	policy statement. References updated.
	01/05/2022 Consensus Review. No change to policy statement. References
	updated.
	01/12/2024 Minor Review. Updated statement from NMN to INV. Updated
	background. New references.
	01/07/2025 Consensus Review. No change to policy statement. Updated
	references.

<u>Top</u>

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company[®], Capital Advantage Assurance Company[®] and Keystone Health Plan[®] Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.